Amplia Therapeutics (Amplia Therapeutics) Margin of Safety % (DCF FCF Based) : N/A (As of Apr. 27, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Amplia Therapeutics Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Amplia Therapeutics's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

Competitive Comparison of Amplia Therapeutics's Margin of Safety % (DCF FCF Based)

For the Biotechnology subindustry, Amplia Therapeutics's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amplia Therapeutics's Margin of Safety % (DCF FCF Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Amplia Therapeutics's Margin of Safety % (DCF FCF Based) falls into.

Amplia Therapeutics Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Amplia Therapeutics's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Amplia Therapeutics (Amplia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amplia Therapeutics Ltd (OTCPK:INNMF) » Definitions » Margin of Safety % (DCF FCF Based)

Comparable Companies

Traded in Other Exchanges

ATX:Australia

Address

350 Queen Street, Level 17, Melbourne, VIC, AUS, 3000

Website

https://www.ampliatx.com

Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

Amplia Therapeutics (Amplia Therapeutics) Headlines

From GuruFocus

FDA CLEARANCE OF AMPLIA'S IND FOR PANCREATIC CANCER TRIAL IN US

By PRNewswire • 01-18-2024

AACR OVARIAN CANCER CONFERENCE PRESENTATION

By PRNewswire • 10-09-2023

AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer

By PRNewswire PRNewswire • 05-29-2023